|
1
|
Kenmotsu H, Naito T, Mori K, Ko R, Ono A,
Wakuda K, Imai H, Taira T, Murakami H, Endo M and Takahashi T:
Effect of platinum-based chemotherapy for non-small cell lung
cancer patients with interstitial lung disease. Cancer Chemother
Pharmacol. 75:521–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minegishi Y, Sudoh J, Kuribayasi H,
Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The
safety and efficacy of weekly paclitaxel in combination with
carboplatin for advanced non-small cell lung cancer with idiopathic
interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shukuya T, Ishiwata T, Hara M, Muraki K,
Shibayama R, Koyama R and Takahashi K: Carboplatin plus weekly
paclitaxel treatment in non-small cell lung cancer patients with
interstitial lung disease. Anticancer Res. 30:4357–4361.
2010.PubMed/NCBI
|
|
4
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Isobe K, Hata Y, Sakamoto S, Takai Y,
Shibuya K and Homma S: Clinical characteristics of acute
respiratory deterioration in pulmonary fibrosis associated with
lung cancer following anti-cancer therapy. Respirology. 15:88–92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Minegishi Y, Takenaka K, Mizutani H, Sudoh
J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, et al:
Exacerbation of idiopathic interstitial pneumonias associated with
lung cancer therapy. Intern Med. 48:665–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
American Thoracic Society; European
Respiratory Society: American Thoracic society/European respiratory
society international multidisciplinary consensus classification of
the idiopathic interstitial pneumonias. This joint statement of the
American thoracic society (ATS) and the European respiratory
society (ERS) was adopted by the ATS board of directors, June 2001
and by the ERS executive committee, June 2001. Am J Respir Crit
Care Med. 165:277–304. 2002.PubMed/NCBI
|
|
13
|
Ozawa Y, Suda T, Naito T, Enomoto N,
Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H and Chida
K: Cumulative incidence of and predictive factors for lung cancer
in IPF. Respirology. 14:723–728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kondoh Y, Taniguchi H, Kawabata Y, Yokoi
T, Suzuki K and Takagi K: Acute exacerbation in idiopathic
pulmonary fibrosis. Analysis of clinical and pathologic findings in
three cases. Chest. 103:1808–1812. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M,
Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, et
al: Interstitial lung disease in Japanese patients with lung
cancer: A cohort and nested case-control study. Am J Respir Crit
Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kenmotsu H, Naito T, Kimura M, Ono A,
Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T,
et al: The risk of cytotoxic chemotherapy-related exacerbation of
interstitial lung disease with lung cancer. J Thorac Oncol.
6:1242–1246. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Socinski MA, Bondarenko I, Karaseva NA,
Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, et al: Weekly nab-paclitaxel in combination with
carboplatin versus solvent-based paclitaxel plus carboplatin as
first-line therapy in patients with advanced non-small-cell lung
cancer: Final results of a phase III trial. J Clin Oncol.
30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raghu G, Rochwerg B, Zhang Y, Garcia CA,
Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et
al: An official ATS/ERS/JRS/ALAT clinical practice guideline:
Treatment of idiopathic pulmonary fibrosis. An update of the 2011
clinical practice guideline. Am J Respir Crit Care Med. 192:e3–e19.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe
S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al:
Double-blind, placebo-controlled trial of pirfenidone in patients
with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
171:1040–1047. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm cooperative study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimizu R, Fujimoto D, Kato R, Otoshi T,
Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A,
et al: The safety and efficacy of paclitaxel and carboplatin with
or without bevacizumab for treating patients with advanced
nonsquamous non-small cell lung cancer with interstitial lung
disease. Cancer Chemother Pharmacol. 74:1159–1166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Enomoto Y, Kenmotsu H, Watanabe N, Baba T,
Murakami H, Yoh K, Ogura T, Takahashi T, Goto K and Kato T:
Efficacy and safety of combined carboplatin, paclitaxel, and
bevacizumab for patients with advanced non-squamous non-small cell
lung cancer with pre-existing interstitial lung disease: A
retrospective multi-institutional study. Anticancer Res.
35:4259–4263. 2015.PubMed/NCBI
|
|
23
|
Sekine A, Satoh H, Baba T, Ikeda S, Okuda
R, Shinohara T, Komatsu S, Hagiwara E, Iwasawa T, Ogura T and Kato
T: Safety and efficacy of S-1 in combination with carboplatin in
non-small cell lung cancer patients with interstitial lung disease:
A pilot study. Cancer Chemother Pharmacol. 77:1245–1252. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim DS, Park JH, Park BK, Lee JS,
Nicholson AG and Colby T: Acute exacerbation of idiopathic
pulmonary fibrosis: Frequency and clinical features. Eur Respir J.
27:143–150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Konishi K, Gibson KF, Lindell KO, Richards
TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et
al: Gene expression profiles of acute exacerbations of idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. 180:167–175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wootton SC, Kim DS, Kondoh Y, Chen E, Lee
JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, et al: Viral
infection in acute exacerbation of idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med. 183:698–702. 2011. View Article : Google Scholar
|
|
27
|
Ushiki A, Yamazaki Y, Hama M, Yasuo M,
Hanaoka M and Kubo K: Viral infections in patients with an acute
exacerbation of idiopathic interstitial pneumonia. Respir Investig.
52:65–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Richeldi L, du Bois RM, Raghu G, Azuma A,
Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
et al: Efficacy and safety of nintedanib in idiopathic pulmonary
fibrosis. N Engl J Med. 370:2071–2082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Manzo A, Carillio G, Montanino A, Costanzo
R, Sandomenico C, Rocco G and Morabito A: Focus on nintedanib in
NSCLC and other tumors. Front Med (Lausanne). 3:682016.PubMed/NCBI
|
|
30
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
